ATE378047T1 - Benzothiazol-derivate zur behandlung von diabetes - Google Patents

Benzothiazol-derivate zur behandlung von diabetes

Info

Publication number
ATE378047T1
ATE378047T1 AT04787110T AT04787110T ATE378047T1 AT E378047 T1 ATE378047 T1 AT E378047T1 AT 04787110 T AT04787110 T AT 04787110T AT 04787110 T AT04787110 T AT 04787110T AT E378047 T1 ATE378047 T1 AT E378047T1
Authority
AT
Austria
Prior art keywords
unsubstituted
substituted
treatment
benzothiazole derivatives
group
Prior art date
Application number
AT04787110T
Other languages
English (en)
Inventor
Pascale Gaillard
Jean-Pierre Gotteland
Pierre-Alain Vitte
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE378047T1 publication Critical patent/ATE378047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
AT04787110T 2003-09-12 2004-09-08 Benzothiazol-derivate zur behandlung von diabetes ATE378047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03102740 2003-09-12

Publications (1)

Publication Number Publication Date
ATE378047T1 true ATE378047T1 (de) 2007-11-15

Family

ID=34306921

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787110T ATE378047T1 (de) 2003-09-12 2004-09-08 Benzothiazol-derivate zur behandlung von diabetes

Country Status (18)

Country Link
US (2) US20070088017A1 (de)
EP (1) EP1696909B1 (de)
JP (1) JP5021307B2 (de)
AT (1) ATE378047T1 (de)
AU (1) AU2004271740B2 (de)
CA (1) CA2534314C (de)
CY (1) CY1107820T1 (de)
DE (1) DE602004010178T2 (de)
DK (1) DK1696909T3 (de)
ES (1) ES2297494T3 (de)
HK (1) HK1096594A1 (de)
HR (1) HRP20070527T3 (de)
IL (1) IL174250A (de)
NO (1) NO20061600L (de)
PL (1) PL1696909T3 (de)
PT (1) PT1696909E (de)
SI (1) SI1696909T1 (de)
WO (1) WO2005025567A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
KR101202240B1 (ko) 2006-08-24 2012-11-16 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
RU2717835C2 (ru) 2012-07-13 2020-03-26 Джи Ти Икс, ИНК. Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
WO2017025980A2 (en) * 2015-08-12 2017-02-16 Shoolineuniversity Of Biotechnology And Management Sciences Novel benzothiazole derivatives with enhanced biological activity
US11905260B1 (en) 2023-10-13 2024-02-20 King Faisal University N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
US11970467B1 (en) 2023-10-13 2024-04-30 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1110957A1 (de) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazolderivate und ihre Verwendung als JNK Modulatoren
DK1450792T3 (da) * 2001-12-07 2007-01-29 Applied Research Systems Benzazolderivater til behandling af sclerodermia
ATE383356T1 (de) * 2002-04-25 2008-01-15 Serono Lab Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns- systems

Also Published As

Publication number Publication date
PT1696909E (pt) 2007-12-21
WO2005025567A1 (en) 2005-03-24
HRP20070527T3 (en) 2007-12-31
DE602004010178T2 (de) 2008-09-11
IL174250A (en) 2011-01-31
JP2007505083A (ja) 2007-03-08
HK1096594A1 (en) 2007-06-08
EP1696909B1 (de) 2007-11-14
DK1696909T3 (da) 2008-01-02
CA2534314C (en) 2012-11-13
IL174250A0 (en) 2006-08-01
JP5021307B2 (ja) 2012-09-05
AU2004271740A1 (en) 2005-03-24
NO20061600L (no) 2006-04-07
CA2534314A1 (en) 2005-03-24
AU2004271740B2 (en) 2010-10-28
US20070088017A1 (en) 2007-04-19
US20140107116A1 (en) 2014-04-17
CY1107820T1 (el) 2013-06-19
PL1696909T3 (pl) 2008-04-30
DE602004010178D1 (de) 2007-12-27
EP1696909A1 (de) 2006-09-06
ES2297494T3 (es) 2008-05-01
SI1696909T1 (sl) 2008-02-29

Similar Documents

Publication Publication Date Title
NO20061600L (no) Bensotiazol-derivater for behandling av diabetes
NO20061614L (no) Benzimidazolacetonitriler
ATE557030T1 (de) Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
ATE427926T1 (de) Cycloalkylaminderivate
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
BRPI0406761A (pt) Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
DE60325740D1 (de) Verwendung von protein-kinase-n-beta
SE0102299D0 (sv) Compounds
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
MA28339A1 (fr) Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments
DE502006007587D1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
CY1112466T1 (el) ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1
CY1113736T1 (el) Ετεροαρυλ-ουριες και η χρηση τους ως ενεργοποιητες γλυκοκινασης
ATE435235T1 (de) Formulierungen glp-1-analoger fusionsproteine
CY1107398T1 (el) Νεα διφαινυλαζητιδoνη με βελτιωμενες φυσιολογικες ιδιοτητες, η διαδικασια για την παραγωγη της, το φαρμακευτικο παρασκευασμα που περιεχει τις ενωσεις αυτες καθως και η χρηση του
NO20061599L (no) Benzoksazol acetonitriler
ATE455772T1 (de) Alkinylarylcarbonsäureamide
TW200740786A (en) Novel cercosporamide derivatives
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
DK1656139T3 (da) Aryldicarboxamider
NO20054148L (no) Nytt medikament
TWI256952B (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1696909

Country of ref document: EP

EEFA Change of the company name